Rakovina Therapeutics Upsizes Financing to $2 Million for Near-Term Operations

Rakovina Therapeutics Inc ( (TSE:RKV) ) has issued an announcement.

Rakovina Therapeutics has upsized its previously announced financing to raise up to $2 million through a combination of a $1 million unsecured convertible debenture with accompanying warrants and a concurrent non-brokered private placement of up to 8,333,334 common shares at $0.12 per share. The proceeds are intended to provide near-term working capital to support ongoing corporate activities and strategic initiatives, with the transactions remaining subject to corporate and regulatory approvals, including from the TSX Venture Exchange, and all issued securities to be subject to a statutory hold period under Canadian securities laws.

More about Rakovina Therapeutics Inc

Rakovina Therapeutics Inc. is a biopharmaceutical research company focused on developing innovative cancer treatments that target the DNA-damage response. The company leverages proprietary AI-powered platforms, Deep-Docking and Enki, to accelerate the review and optimization of drug candidates and aims to advance its pipeline of DNA-damage response inhibitors into human clinical trials with pharmaceutical partners.

Average Trading Volume: 38,275

Technical Sentiment Signal: Sell

Current Market Cap: C$3.17M

For detailed information about RKV stock, go to TipRanks’ Stock Analysis page.